NCT07188896 2026-04-03
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
University of Oklahoma
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
University of Wisconsin, Madison